Altasciences is expanding its North American bioanalytical laboratory network through new capacity in Greater Montréal and a purpose-built laboratory in Harleysville, Pennsylvania, as the contract research organization responds to demand for late-stage clinical bioanalysis.
The company said a 4,000-square-foot addition to its Greater Montréal laboratory is expected to be fully operational by the end of the third quarter of 2026. Altasciences also plans to open a new 13,000-square-foot laboratory in Harleysville, with the first phase of construction scheduled for completion in the first quarter of 2027.
The expansion is intended to increase the company’s ability to manage larger studies and higher sample volumes while supporting increasingly complex drug-development programs. The new and expanded facilities will include advanced laboratory automation and instrumentation for pharmacokinetic and pharmacodynamic assay method development, validation and sample analysis across clinical development phases.
Altasciences said the additional space and streamlined workflows are expected to reduce turnaround times for bioanalytical data. Faster data delivery could help sponsors make development decisions sooner and keep clinical programs moving forward, the company said.
The investments also add operational flexibility and resilience for clients conducting late-stage trials. Altasciences said its broader North American bioanalytical network includes established laboratories in Greater Montréal, Seattle, Washington, and Columbia, Missouri. Together, those sites support programs ranging from nonclinical research through late-stage clinical development.
The company said its harmonized scientific operations are designed to provide capacity, scalability and business continuity for sponsors, particularly for global clinical trials. The expansion reinforces Altasciences’ strategy of offering integrated support across the drug-development continuum, from early research through later-stage clinical work.
Altasciences described the new investments as a response to growing industry demand for bioanalytical services capable of handling complex development programs and large-scale sample analysis. The company said the expanded facilities will provide sponsors with greater flexibility while helping accelerate the delivery of critical clinical data.